Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 29c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.56), $0.29 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $246 million versus the consensus estimate of $199.24 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2026 revenue of $875-900 million, versus the consensus of $811.3 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight